{"id":"W3107792394","doi":"10.1182/bloodadvances.2020003314","title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Astex Pharmaceuticals; Jazz Pharmaceuticals; Medical Research Council; Celgene; Gilead Sciences; Alexion Pharmaceuticals; Astellas Pharma; TG Therapeutics; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Adverse effect; Anemia; Pharmacokinetics; Internal medicine; Randomized controlled trial; Pharmacodynamics; Gastroenterology; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002758558,0.0002549177,0.0005598473,0.000036223,0.0001546987,0.00003171129,0.0002041258,0.00006746389,0.00004212636],"category_scores_gemma":[0.001495625,0.000137835,0.000153884,0.0003287671,0.000084217,0.0001706626,0.00007710478,0.0002604698,0.000008033016],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002723619,"about_ca_system_score_gemma":0.00007629508,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003989816,"about_ca_topic_score_gemma":0.0001575549,"domain_scores_codex":[0.9979958,0.0001981663,0.0007072455,0.0004624414,0.0003338506,0.00030251],"domain_scores_gemma":[0.9967963,0.002344795,0.0003185294,0.0003564349,0.00007291125,0.0001110974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1220904,0.003152564,0.489689,0.0001791724,0.0008501784,0.0001813256,0.01937597,0.0001460037,0.007875241,0.0005106759,0.001273964,0.3546756],"study_design_scores_gemma":[0.4020757,0.009875149,0.4072156,0.001693389,0.0009865235,0.00001186058,0.007905834,0.0001909749,0.12892,0.0006759202,0.0397156,0.0007334923],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9801775,0.001489345,0.000004129021,0.01524012,0.00021313,0.001310492,0.000205576,0.00003984141,0.001319843],"genre_scores_gemma":[0.994329,0.001176717,0.00228502,0.001473566,0.000399189,0.0002124324,0.0000784174,0.00002527519,0.00002038369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3539421,"threshold_uncertainty_score":0.562075,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05893450828529068,"score_gpt":0.3189789532074175,"score_spread":0.2600444449221268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}